Ginsenoside Rh1 (Synonyms:人参皂苷 Rh1; Prosapogenin A2; Sanchinoside B2; Sanchinoside Rh1)
目录号 : KM16819 CAS No. : 63223-86-9 纯度 : ≥98%

Ginsenoside Rh1 (Prosapogenin A2) 抑制 PPAR-γ,TNF-α,IL-6 和 IL-1β 的表达。

规格 价格 是否有货 数量
5mg
In-stock
10mg
In-stock
50mg 询价 In-stock
100mg 询价 In-stock

Other Forms of Rapamycin:

KKL Med 的所有产品和服务仅用于科学研究,不能被用于人体,兽医,我们也不向个人提供产品和服务。
生物活性

Ginsenoside Rh1 (Prosapogenin A2) inhibits the expression of PPAR-γ, TNF-α, IL-6, and IL-1β.

体外研究

The effect of Ginsenoside Rh1 is examined on adipogenesis in 3T3-L1 cells. Ginsenoside Rh1 potently inhibits the adipogenesis, as assessed by Oil-red O staining and lipid contents in 3T3-L1 adipocytes. Ginsenoside Rh1, at concentrations of 50 μM and 100 μM, inhibit the adipogenesis by 50% and 63%, respectively.The expression levels of adipocytespecific genes such as PPAR-γ, C/EBP-α, FAS, aFABP and some genes are examined during early phase of differentiation such as Pref-1, C/EBP-δ and Glucocorticoid receptor (GR). After the treatment with Ginsenoside Rh1 in 3T3-L1 cells, mRNA is extracted on 18 h and 24 h for Pref-1, C/EBP-δ and GR and day 8 for PPAR-γ, C/EBP-α, FAS, aFABP. Then, the expression profiles of adipocyte-specific genes are investigated by RT-PCR. PPAR-γ, C/EBP-α, FAS, and aFABP expressions are significantly increased in DMI-stimulated differentiated adipocyte compared to those of non-stimulated adipocyte cells. However, treatment with DMI in the presence of Ginsenoside Rh1 significantly suppresses the expression levels of PPAR-γ, C/EBP-α, FAS, and aFABP in a dose- dependent manner, whereas the expression levels of Pref-1, C/EBP-δ and GR are not affected.

体内研究

When high-fat diet (HFD) fed mice for 8 weeks, body and epididymal fat weight gains are significantly increased compared to those of low-fat diet (LFD)-fed mice. However, when Ginsenoside Rh1 is treated in HFD-fed mice, body and epididymal fat weight gains are significantly decrease compared with those of the HFD-fed mice. TG, glucose, insulin, total cholesterol, and HDL levels in the blood are significantly increased in HFD-fed mice group compared to LFD-fed mice group. Treatment with Ginsenoside Rh1 in HFD-fed mice significantly lowers TG level alone.

分子式
C36H62O9
分子量
638.87
CAS号
63223-86-9
中文名称
人参皂苷 Rh1;人参皂苷 Rh1
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 100 mg/mL (156.53 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.5653 mL 7.8263 mL 15.6526 mL
5 mM 0.3131 mL 1.5653 mL 3.1305 mL
10 mM 0.1565 mL 0.7826 mL 1.5653 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (3.91 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (3.91 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (3.91 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (3.91 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (3.91 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (3.91 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

科研文献
The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
在线客服
咨询热线
400-881-9290
关注微信公众号